cidrap.umn7h
Real-world study: RSV vaccine 78% to 80% effective against infection, severe illness in older US veterans
The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...
pulmonologyadvisor13h
FDA Alert: Pulmonology Drug Approvals, Recalls, and Device Updates
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
Medscape2d
RSV Vaccines Will Carry Warning for Guillain-Barré Syndrome
The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...
After a Reset Year, Is Moderna Stock Poised for a Comeback?
The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.
pulmonologyadvisor3d
RSV Vaccine Labeling Updated With Guillain-Barré Syndrome Warning
The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...
GlaxoSmithKline: Sell Rating Amidst Weak Vaccine Performance and Projected EPS Decline
GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...